Should You Buy, Sell, Or Hold Reckitt Benckiser Group Plc’s Spinoff, Indivior PLC?

Should you buy, sell, or hold Reckitt Benckiser Group Plc’s (LON: RB) spinoff, Indivior PLC (LON: INDV)?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Reckitt Benckiser (LSE: RB) recently completed the much-anticipated spinoff of its pharmaceuticals division in to a new company named Indivior (LSE: INDV).

Reckitt’s shareholders received one Indivior share for every Reckitt share they held and the market seemed to welcome Indivior with open arms. The pharma company’s stock jumped as much as 17% in the first few hours of trading on 24 December. 

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

However, after a successful spinoff, investors now need to ask whether or not Indivior deserves a place within their portfolio? Is the company a good long-term investment, or should you steer clear?

Looking to grow

Indivior’s main product is Sub­oxone, a heroin addiction drug. The company lost its patent-provided exclusivity on the product in 2009 and since then sales have been sliding.

Between 2004 and 2011 sales of Suboxone climbed from £89 to £762m but City analysts believe that Indivior’s revenues will decline by about 12.5% this year to £680m, while operating profits are predicted to fall nearly a fifth to £345m. 

However, the company is working on the development of several other products including a treatment for schizophrenia and four other treatments for opioid dependence, cocaine intoxication and alcohol abuse. The schizophrenia treatment is in the final stages of development, while the other treatments are all in early stages of development. 

So over the next few years, if all goes to plan, Indivior will diversify into other markets and reduce its dependence upon Suboxone. 

Plenty of potential 

Additionally, as a long-term pharmaceutical play, Indivior certainly has plenty of potential. For example, according to management twelve million people abuse opioids annually in the US and 2.5m of them need treatment for addiction. At present, Indivior is only treating 450,000 patients for opioid abuse. About three-quarters of cases involve opioid-based painkillers, rather than heroin. 

What’s more, Indivior’s management has noticed a global shift in treating drug addiction over the past few years. Addiction is now treated as chronic disease, rather than as something to be punished. A shift that is pushing governments to change their stance and fund treatments instead of imprisonment.

Buy, sell, or hold?

All in all, Indivior has room to grow over the long-term as it benefits from the rising demand for addiction treatment and the launch of new products. But is the company a buy at present levels?

Well, as Indivior has only just become a public company City analysts have yet to publish any definitive figures on the company’s valuation, profitability and outlook. That being said, it’s widely expected that Indivior’s sales set to fall to £680m this year, which means the company is trading at a price to sales ratio of 1.5.

On average, the biotech sector trades at a P/S ratio of around 3.5, indicating that Indivior is undervalued at present levels. Nevertheless, Indivior is overly reliant upon one treatment and sales are falling. Although, with an operating margin of around 50%, a hefty dividend payout is likely to be on the cards. 

The bottom line

Overall, Indivior appears cheap but the company’s sales are falling. For this reason, Indivior could be too risky for some investors.

More on Investing Articles

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

UK shares: 1 cheap dividend stock I bought to combat inflation!

This Fool is on the lookout for the best UK shares to protect himself from soaring inflation. Here is one…

Read more »

Smiling senior white man talking through telephone while using laptop at desk.
Investing Articles

A beaten-down penny stock to buy on the dip!

This penny stock is down 12% in just a few weeks. But at the current price, it looks like a…

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

Should I buy Marks and Spencer shares for its growth in July?

Despite posting excellent annual results, Marks and Spencer shares are down 40% this year. Could this be a buying opportunity…

Read more »

Stack of one pound coins falling over
Investing Articles

The Lloyds dividend could keep growing – but will it?

Our writer explains why he's not taking the prospect of a growing Lloyds dividend for granted.

Read more »

Shot of an young Indian businesswoman sitting alone in the office at night and using a digital tablet
Investing Articles

Are BT shares a good buy at 185p?

BT shares offer a fairly attractive dividend and are down considerably over four years. But is this stock right for…

Read more »

An airplane on a runway
Investing Articles

The Rolls-Royce share price is down one-third. Should I buy?

The Rolls-Royce share price has lost a third of its value since the year began. Our writer explains why he…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

Down 57%, cheap NIO shares are ‘no-brainer’ additions to my portfolio!

NIO shares have risen considerably in recent months, but are down over the year. I'm still buying this stock for…

Read more »

Young woman with face mask using mobile phone and buying groceries in the supermarket during virus pandemic.
Investing Articles

Will a recession help or hurt the B&M share price?

The B&M share price has been tumbling and there's a recession looming, So why would our writer still consider adding…

Read more »